Health Care • Biotechnology: Pharmaceutical Preparations
$10.26 ▼ -0.30
(-2.84%)
MKT CAP: $939.4M • VOL: 2.25M
52W L $7 52W H $14
KURA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $67.5M | $53.9M | $0 |
| YoY Revenue Growth % | +25.2% | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$303.6M | -$193.2M | -$165.8M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$278.7M | -$174.0M | -$152.6M |
| EBITDA (Normalized) | -$298.3M | -$192.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$64.1M | $134.3M | -$124.8M |
| Capital Expenditures (CapEx) | $6.6M | $472.0K | — |
| Free Cash Flow (FCF) | -$70.7M | $133.8M | -$124.8M |
| FCF Margin % | -80.0% | 80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $149.1M | $224.5M | — |
| Total Debt (Short + Long Term) | $9.7M | $6.9M | — |
| Total Stockholders' Equity | $174.1M | $413.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR KURA.